Zacks: IsoRay, Inc. (ISR) Given Average Recommendation of “Buy” by Analysts

Share on StockTwits

IsoRay, Inc. (NASDAQ:ISR) has been given an average broker rating score of 2.00 (Buy) from the two analysts that cover the company, Zacks Investment Research reports. One research analyst has rated the stock with a hold rating and one has assigned a strong buy rating to the company. IsoRay’s rating score has improved by 25.1% from 90 days ago as a result of various analysts’ ratings changes.

Brokers have set a 12 month consensus price objective of $0.85 for the company and are expecting that the company will post ($0.02) EPS for the current quarter, according to Zacks. Zacks has also given IsoRay an industry rank of 52 out of 255 based on the ratings given to its competitors.

Separately, HC Wainwright restated a “buy” rating on shares of IsoRay in a research report on Monday, January 28th.

Shares of NASDAQ:ISR opened at $0.38 on Friday. IsoRay has a twelve month low of $0.27 and a twelve month high of $1.22.

IsoRay (NASDAQ:ISR) last issued its quarterly earnings data on Tuesday, February 12th. The company reported ($0.02) earnings per share for the quarter, hitting the consensus estimate of ($0.02). The company had revenue of $1.90 million for the quarter, compared to analysts’ expectations of $1.76 million.

IsoRay Company Profile

IsoRay, Inc, through its subsidiary, IsoRay Medical, Inc, develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States. The company produces CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers, as well as ocular melanoma.

Featured Article: What is the Ex-Dividend Date in Investing?

Get a free copy of the Zacks research report on IsoRay (ISR)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for IsoRay Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IsoRay and related companies with's FREE daily email newsletter.